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ABSTRACT A strategy has been developed to express and
purify a recombinant, nonfunctional axial-ligand mutant of
iso-1-cytochrome c (Met-80--+ Ala) in Saccharomyces cerevisiae
in quantities necessary for extensive biophysical characteriza-
tion. It involves coexpressing in the same plasmid (YEp213) the
nonfunctional gene with a functional gene copy for comple-
mentation in a selective medium. The functional gene encodes
a product with an engineered metal-chelating dihitdine site
(His-39 and Leu-58 -* His) that enables efficient separation of
the two isoforms by immobilized metal-affinity chromatogra-
phy. The purified Met-80 -* Ala protein possesses a binding
site for dioxygen and other exogenous ligands. Absorption
spectra of several derivatives of this mutant show striking
similarities to those of corresponding derivatives of horse-
radish peroxidase, myoglobin, and cytochrome P450. The use
ofa dual-gene vector for cytochrome c expression together with
metal-affnity separation opens the way for the engineering of
variants with dramatically altered structural and catalytic
properties.
Cytochrome c (1, 2) has been a benchmark for studies of
eukaryotic transcription (3), protein folding and stability (4),
protein engineering (5), and long-range electron transfer (6).
Because ofthe requirement ofposttranslational heme attach-
ment, the expression (either homologous or heterologous) of
mitochondrial cytochromes c has been largely limited to
eukaryotic organisms, the most favored of which is baker's
yeast (Saccharomyces cerevisiae). Smith and coworkers (7)
have utilized a multicopy plasmid (YEp) for overexpressing
yeast iso-l-cytochrome c under the control of its natural
promoter. The host cells are grown in nonfermentable carbon
medium where cytochrome c expression is fully derepressed
and a functional gene product is required for aerobic respi-
ration. Other groups (8, 9) have used integrative vectors that
result in a single-copy gene of cytochrome c. Having a
chromosomal gene copy allows expression of the protein
either in a rich or in a lactate medium.
While a great many cytochrome c mutants have been
generated by recombinant DNA techniques, only those vari-
ants that retain significant wild-type electron transfer activity
have been isolated in reasonable yields. With the exception
of His-18 -- Arg yeast cytochrome c (10), these exclude
replacements of the axial ligands (His-18 and Met-80) or the
cysteine residues (positions 14 and 17) that provide the
covalent heme linkages (11). Thus, the development of a
more general expression system for cytochrome c is of
considerable interest; such a system would greatly expand
the possible structural changes that could be incorporated
into this paradigmatic protein.
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In this paper, we report an expression system using a YEp
vector bearing both the target nonfunctional variant as well
as the functional cytochrome c gene to support the growth of
the yeast cells in medium containing a nonfermentable carbon
source. To facilitate the purification of the functional protein
from the target nonfunctional mutant protein, a dihistidine
chelating site (His-39, Leu-58 -+ His) was engineered onto
the surface of the functional protein so that the two isoforms
could be separated by immobilized metal-affinity chromatog-
raphy (12, 13). The initial target protein was chosen to be
Met-80 -- Ala iso-1-cytochrome c (M80A) for the following
reasons. First, studies by Sherman et al. (14) have shown that
yeast cells containing Met-80 mutant proteins (Met-80-- Arg,
Thr, Ile) maintain certain levels of holoproteins (120% of
native protein), and their in vitro levels ofheme incorporation
and mitochondrial transport also are similar to those of the
native protein. Although no mutants were isolated, a result
that has been attributed to instability of the proteins, the
above experiments indicate that they can be made in vivo.
Second, several semisynthetic Met-80 mutant proteins of
horse heart cytochrome c have been prepared and shown to
be stable species (15-17). Finally, replacing Met-80 with
alanine creates a binding site for dioxygen (16, 17), which
represents an important step in the engineering of artificial
oxygenases (18).
MATERIALS AND METHODS
Site-Directed Mutagenesis and Molecular Cloning. Muta-
tions in the yeast iso-l-cytochrome c (cycl) gene were
introduced by using standard oligonucleotide-directed muta-
genesis protocols (19) and confirmed by dideoxynucleotide
DNA sequencing (20). YEp213/Leu58Hiscycl (F. H. Ar-
nold) (13) was digested with Sma I and HindlIl; the 1.1-kb
fragment containing a functional cytochrome c gene (His39/
Leu58Hiscycl+) was isolated by agarose gel electrophoresis
and the silica bead adsorption-elution protocol (Qiagen,
Chatsworth, CA). The fragment was cloned into the Hindlll
site of YEp213/Met8OAlacycl using a phosphorylated Hind-
III linker (5'-CCCAAGCTTGGG-3') from Stratagene.
Protein Expression and Purification. S. cerevisiae GM3C2
strain (MATa leu2-3 leu2-112 trpl-1 his4-519 cyci-1 cyp3-1)
(21) was transformed with the YEp213 hybrid vectors by
electroporation (22). The mutant proteins were expressed by
growing the cells to saturation on a glycerol-based medium
(YPG = 1% Bacto yeast extract, 2% Bacto peptone, and 3%
glycerol) at 30°C. Cell lysis and preliminary protein purifi-
cation (i.e., ammonium sulfate precipitation, Sepharose
CM52 ion-exchange chromatography) were according to es-
tablished procedures (23). The ensuing chromatographic runs
were carried out on an FPLC system from Pharmacia LKB.
Abbreviations: HRP, horseradish peroxidase; M80A, Met-80 -- Ala
iso-l-cytochrome c.
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FIG. 1. (A) Vector construct for expression of Met-80 -. Ala (cycl-) and Leu-58 -- His (cycl+) cytochrome c. The shaded boxes contain
the promoter and upstream activation sequences for cycl transcription. Leu2 + and ampicillin resistance markers also are present for plasmid
selection in yeast and Escherichia coli, respectively. (B) Molecular model of Leu-58 -- His cytochrome c, indicating the location of the surface
dihistidine site for high-affinity binding to immobilized metal complexes. (C) Chromatogram showing the purification on a copper(II)
iminodiacetate column of homogenized protein extracts containing the nonfunctional M80A (band I) and the functional His-39/Leu-58 -* His
proteins (band II, ferrous; band III, ferric form).
The protein extracts were loaded onto a 5-ml HiTrap che-
lating column (Pharmacia LKB) that was charged with 2.5 ml
of 100 mM CuS04. The proteins were eluted with a 1-20 mM
imidazole gradient in 50 mM sodium phosphate/500 mM
NaCl, pH 7.0. The band containing the M80A mutant protein
bound weakly to the column and was subsequently purified
to homogeneity by ion-exchange chromatography using a
Mono S HR 16/10 column (Pharmacia LKB) with a 0-1 M
NaCl gradient in 50 mM sodium phosphate (pH 7.0).
Protein Characterization. The purity and identity of the
M80A protein were established by SDS/PAGE and amino
acid sequencing. The holoprotein (0.7 mM solution in 70%
formic acid) was incubated with a 130-fold excess of cyano-
gen bromide for 46 hr. The reaction mixture was exchanged
by ultrafiltration to 100mM NH4HCO3 (pH 8.0), lyophilized,
and run through a Pharmacia ProRPC HR 5/10 column in
order to isolate the 65-103 fragment. Sites of heme attach-
ment (Cys-14 and Cys-17) and the mutation at position 80
were confirmed by NH2-terminal sequencing of the holopro-
tein and of the 65-103 cyanogen bromide fragment, respec-
tively. Sequences were confirmed via automated Edman
degradation on an Applied Biosystems 473A sequencer.
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Horseradish peroxidase (HRP) and horse heart myoglobin
(Mb) were obtained from Sigma; Pseudomonas putida cy-
tochrome P450C,, (induced by growth on camphor; J. H.
Dawson, University of South Carolina) was purified by T.
Pascher (Beckman Institute, Pasadena, CA). The oxy and
carbon monoxy forms ofHRP were prepared according to D.
Keilin and E. F. Hartree (24). The deoxy derivatives of both
proteins were made under a nitrogen atmosphere by adding
excess Na2S204 to the protein solutions and running the
solution through a Sephadex G-25 column. Exposing the
deoxy form ofthe M80A protein to air results in the oxy form;
and exposure of the protein to carbon monoxide yields the
carbon monoxy derivative. The thiomethoxide derivative of
the M80A protein was obtained by adding a 500-fold excess
ofNaSCH3 to a ferric-M80A protein solution. The imidazole
derivative of cyt P450Cm was prepared according to Rux and
Dawson (25). Electronic absorption spectra were measured
at room temperature on a Cary 14 spectrophotometer. Ex-
tinction coefficients were determined by the pyridine hemo-
chrome method (26).
Molecular Modeling. Energy-minimization calculations on
His-39/Leu-58 -) His cytochrome c were performed on the
Wavelength, nm
FIG. 2. Electronic absorption spectra of ferrous M80A derivatives (A) and analogous HRP species (B). The proteins were in 50 mM sodium
phosphate buffer (pH 7.0).
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Table 1. Electronic absorption data for selected heme proteins
Anm, nm
Protein 8 Soret (v) Visible (a, .8)/near-IR
Ferrous derivatives
M80A, deoxy 327 (354, sh) 410 (437, sh) 521 (sh) 548 564 (sh)
HRP, deoxy 382 437 519 (sh) 558 589 (sh)
Mb, deoxy 435 559
M80A, oxy 351 408 537 570
HRP, oxy 354 417 544 578
Mb, oxy 348 417 544 580
M80A, carbon monoxy 345 (394, sh) 414 531 554
HRP, carbon monoxy 350 423 542 572
Mb, carbon monoxy 346 423 540 579
Ferric derivatives
M80A (pH 3.5) 398 494 624
HRP 403 498 641
Mb 408 505 633
M80A (pH 7.0) 357 406 536 566 626
HRP (alkaline) 414 542 576 640
Mb (alkaline) 358 411 539 585
M80A, thiomethoxide 355 416 535 566 648 763
Cyt P450, imidazole 358 425 542 574 638 753
M80C* 355 416 540 570 635 734
Sh, shoulder.
*Semisynthetic Met-80 -) Cys horse heart cytochrome c (15).
1.23-A structure of yeast iso-1-cytochrome c (27) using
BIOGRAF version 3.0 (Molecular Simulations, Burlington,
MA).
RESULTS AND DISCUSSION
In the plasmid construct shown in Fig. 1A, identical copies
of the natural promoter region of cycl direct the independent
expression of the two cytochrome c genes. The functional
cytochrome c contains a surface dihistidine site (His-39,
Leu-58 -- His; Fig. 1B) that endows it with a high affinity for
immobilized metal complexes. Transformation of S. cerevi-
siae GM3C2 (21) (strain deficient in both cytochrome c
isozymes) with a YEp213 vector containing the M80A gene
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(cycl-) alone did not show any cell growth on a nonferment-
able carbon medium (YPG), whereas cells harboring the
cycl+/cycl - vector grew as well as those containing only the
cycl + vector.
Cupric iminodiacetate chromatography of the protein ex-
tract (Fig. 1C) revealed three heme-containing bands, two of
which (II and III) were retained strongly on the column and
later identified to be the chelating wild-type protein in dif-
ferent oxidation states (Fe3+/2+). The third band (I) bound
weakly to the column and was further fractionated by cation-
exchange chromatography. The UV/visible spectrum of pu-
rified M80A matches that of the oxyferrous form of the
analogous horse heart mutant prepared by semisynthesis (16,
17). The total amount of cytochromes c purified from this
e. ,-1...
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FIG. 3. Electronic absorption spectra of ferric M80A derivatives (A) and analogous HRP and cytochrome P450w,, (cyt P-450,-) species (B).
All proteins were in 50 mM sodium phosphate buffer (pH 7.0), except for the alkaline form of HRP, which was prepared in 100 mM NaHCO3
(pH 11.4), and the imidazole (Im) derivative of cytochrome P450Cun, which was kept in 100 mM sodium phosphate/88 mM imidazole/22 pLM
camphor, pH 7.0.
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system (2 mg/liter) is comparable to that of other expression
systems used to generate functional iso-1-cytochrome c vari-
ants (7, 8, 23). The M80A mutant protein constitutes 25-30%
(0.5-0.6 mg/liter) of the total cytochromes c purified from
this system; to our knowledge it represents the first recom-
binant, nonfunctional axial-ligand mutant of cytochrome c
produced in quantities that permit extensive biophysical
characterization.
The yeast M80A exhibits nearly all the properties ofaheme
protein with an available sixth ligation site. In the reduced
form, the mutant can either have a vacant coordination site
(deoxy form) or bind small exogenous ligands such as 02 and
CO (Fig. 2A). The spectroscopic properties of the yeast
protein are similar to those of the horse heart M80A variant
(16, 17). In a survey of derivatives of naturally occurring
heme proteins, the closest resemblance can be drawn to HRP
(Fig. 2B and Table 1). The observation that the electronic
absorption bands of the various M80A species are slightly
blue-shifted relative to those of their HRP analogs can be
accounted for by the difference in ir conjugation between c
and b hemes (heme b having two extra vinyl substituents)
(25).
At neutral pH, the UV/visible spectrum of the oxidized
M80A mutant is analogous to that of the alkaline form of
ferri-HRP (Fig. 3). It is likely that the sixth ligand is OH-
rather than H20, since EPR and other spectroscopic mea-
surements are consistent with His-OH- coordination in the
M80A horse heart protein at pH 7 (17). Acid titration of the
mutant produces spectral changes that indicate direct pro-
tonation of the hydroxyl ligand to form the aquoferric deriv-
ative. Interestingly, the pKa (=6.5) is much lower than that
ofhorse Mb (8.9) (28). Addition ofthiomethoxide (CH3S-) to
the oxidized M80A protein results in an absorption spectrum
similar to that of the imidazole derivative of cytochrome
P450Cam, with slight blue shifts attributable to the different
heme types (c vs. b).
Our approach based on the combined use ofa cycl +/cycl -
expression vector and metal-affinity separation expands the
possibilities of incorporating structural changes in regions of
cytochrome c that are not accessible by either semisynthetic
(e.g., region 1-64) (15-17) or previous recombinant DNA
strategies. Using this methodology, we have successfully
expressed and purified a cytochrome c derivative that pos-
sesses unusual ligand-binding properties. Our findings rep-
resent an important step toward the long-term goal of devel-
oping a deeper understanding of heme-mediated processes;
with such an understanding, it should be possible to engineer
useful catalytic functions into cytochrome c and related
heme-containing molecules.
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